## Index

| A | Author anonymity, 222–223  
Authorship credit, 227  
Awrah, 86 |
|---|---|
| Account billing. See Client billing  
Adenomatous polyposis coli (APC), 200  
Adverse medical events  
definition, 38  
disclosure  
caregiver, 41  
definition, 38  
lawsuits, 40  
need for, 38–39  
process of, 39–40  
professional standards, 39  
risk management principles, 39  
special circumstances, 41  
substitution test, 39  
timing of, 39  
melanoma, 37, 42  
MRSA infection, 37, 42  
Age-related skin changes improvement, 143  
Aging, of physician, 98, 102–103  
Alcohol abuse, impaired behavior, 97, 101–102  
American Academy of Dermatology (AAD)  
botulinum toxin injection, 131–132  
conflict of interest management procedure, 188–189  
dermatopathology, 169, 175  
office dispensing and product pricing, 138  
physician extenders, guidance of, 56  
American Board of Dermatology (ABD), 85  
American Medical Association (AMA)  
botulinum toxin injections, 131–132  
dermatopathology, 169, 205  
edermolysis bullosa, 207  
physician advertising, 147–148  
therapeutic privilege, 34  
American Psychiatric Association (APA), 100  
Aromatherapy  
corporate organizational structure, 157, 161  
ethical considerations, 159–160  
flyers, ethical considerations for, 157–158  
legal considerations, 158–159  
legal partnership, 157  
medical directorship, 157, 160–161  
medical spas, 158  
profit-sharing facilitation, 157, 161  
Assent, 26–27  
Atopic dermatitis treatment, conflicts of interest, 185–186  
B | Belmont report, 194, 207, 208, 237  
Best Doctor programs, 149  
Bone marrow biopsies (BMBx), 123  
Botox® and basal cells  
continuing medical education, 133  
cosmetic procedural training, 131, 134–135  
lentigo maligna, 134  
lucrative cosmetic procedures, 134  
medical ethics, 131  
physician assistant, 133  
physician extenders, 133  
primary care, 131, 133, 134  
risk factors in training, 133–134  
telephone tag, 132  
Boundary crossing, 62  
Boundary violation, 62  
Byline integrity. See Ghost busting, dermatology publications  
Bystander phenomenon, 5  
Clinical ethics teaching. See Teaching, for clinical ethics  
Clinical investigator, responsibilities of |
Clinical investigator, responsibilities of (cont.)
ethics of, 194–195
history, 193
psoriasis treatment, 194, 195
research goal, 193
Committee on Publication Ethics (COPE), 229
Confidentiality
breach of, 48
in iPLEDGE program, 21
in pediatric dermatology, 27–28
in telemedicine, 47, 48
Conflicts of interest
atopic dermatitis treatment, 185–186
cutaneous T-cell lymphoma, 185, 189
definition, 186
eliminating, 188
ethical considerations, 186–187
financial, 185
financial inducements, 187
identify and management, 188
non-financial, 189
pharmaceutical and medical device industries, 187
pharmaceutical manufacturer lecture, 185
policies and remedies, 187–188
principles, 189–190
psoriasis treating guidelines, 185, 188–189
Contractual joint venture (CJV), 181–182
Copyright infringement, 234–235
Cosmetic procedural training, 131, 134–135
Council of Medical Specialty Societies
patients, physicians and society, 144
skincare products, 144
Council of Science Editors (CSE), 216
Council on Ethical and Judicial Affairs (CEJA), 84–85
Cross-gender modesty, 86
Cultivation, mentor-mentee relationship, 110
Cultural and linguistic barriers, 84
Cultural competence, 85
Culturally and linguistically appropriate services (CLAS), 85
Cutispas, 157, 160
Cyclin dependent kinase 2A (CDKN2A), 198, 203

D
Data and Safety Monitoring Board (DSMB), 211
Data and Safety Monitoring Committee (DSMC), 211
Data Monitoring Committee (DMC), 211
Declaration of Helsinki, 194
Delusions of parasitosis, 34–35
Dermal nevi, 9, 11
Dermatology publications
ghost busting in
authorship credit, 227
ethical analysis, 229–230
guest authorship, 228
guest management, motivating factors, 228–229
literature, 227
self-plagiarism
copyright infringement, 234–235
duplicate publication, 233–234
elimination of, 236
salami-slicing, 234
solutions, 235–236
text recycling, 235
Dermatopathology
actinic keratosis diagnosis, 171
biopsy specimens samples, 173–174
clinical practice, 169
ethical and legal debate, 169–170
fellowship training, 170
histology laboratory, 169
medical malpractice, 172
pathological quality, 173
patient care, 170
professional judgment, lab, 174
surgical pathology, 171
treatment, 171–172
unethical testimony, 173
Dermethica, 157
Direct billing, 178
Direct-to-consumer (DTC), 203–204
Direct-to-consumer drug advertising (DTCDA)
critics of, 14–16
definition, 15
divisions of, 15
genital warts, 13, 16
help-seeking advertisement, 14
inherently biased nature of, 15
injectable psoriasis medication, 13, 15–16
product claim advertisement, 14
reminder advertisement, 14
Disclosure, adverse medical events
caregiver, 41
definition, 38
lawsuits, 40
need for, 37–39
process of, 39–40
professional standards, 39
risk management principles, 39
special circumstances, 41
substitution test, 39
timing of, 39
Disruptive physician behavior, 103–104
Diverse society, physicians in
bias and prejudice, 84
cultural and linguistic barriers, 84
cultural and religious beliefs, patients, 86
cultural competence, 85
decision-making process in, 85
ethical and professional obligations, 84–85
language barriers, patients, 84–85
physician conscience, 85–86, 88
prejudiced patients, 87
trust, 84
Double-blind peer review, 222
DTCDA. See Direct-to-consumer drug advertising (DTCDA)
Duplicate publication, 233–234

E
Economic value to customer (EVC), 140
Electronic medical record (EMR), 37
Electronic submission management systems, 224
Emancipated minors, 27
Epidermolysis bullosa
  beneficence, 208–209
  clinical research, 206
  definition, 205
  ethical practices development guidelines, 210–211
  justice distribution, 209–210
  research physician, 206–207
  respect for persons, principle of, 207–208
  symptoms, 205
Ethical education for residents. See Residents, ethics education for
Ethnic and racial disparities, 84
Extravagant gifts, 72, 73

F
Facebook, 77
Facebook page, 78
Facebook profile, 78
Facebook wall, 78
Facial hair removal, 149
Family members, treatment to
  common reasons for treating, 68
  immediate, 67
  niece, 68–69
  optimal patient care, 68
  prescription for, 69–70
  refusal of treatment, 67
  risk of involvement, 70
  sister-in-law, 69
Fan Pages, 77
Federal Trade Commission (FTC), 147–148
Financial conflict of interest, 189
Food and Drug Administration (FDA)
  DTCDA, 14
  epidermolysis bullosa, clinical research, 206
  isotretinoin, 20
Formal mentoring, 109–110
Friending and tweeting
  common Web 2.0 Jargon, 78
  doctor-patient relationship, 78
  Fan Pages, 77
  HIPAA violations, 79
  online social networking, 78
  professionalism, 77, 80
  protected health information (PHI), 79
  Twitter, 79
    unprofessional online content, 80–81
Friendly Derm Services (FDS), 177
Futile care, 9

G
Gatekeeper system, ethical implications. See Managed care organizations
Genetic Information Non-Discrimination Act (GINA), 202
Genetic testing, dermatological diseases
  carrier testing, 199
  cyclin dependent kinase 2A, 198
  diagnostic testing, 199
  ethical and legal issues, 199
  mannose-binding lectin gene, 199
  mucocutaneous macules, 197
  neurofibromatosis type 1, 198
  Peutz Jeghers syndrome, 197, 199–201
  pharmacogenetics research, 198
  predictive testing, 199
  prenatal testing, 199
  presymptomatic testing, 199
  risk assessment and treatment, 198
  STK11 gene mutation, 197
  TGM1 gene mutation, 197, 201–202
Genital warts, 13, 16, 26
Ghost authorship, 228
Ghost busting, dermatology publications
  authorship credit, 227
  ethical analysis, 229–230
  ghost authorship, 227, 228
  ghost management, motivating factors, 228–229
  guest authorship, 227–228
  literature, 228
Ghost management, motivating factors, 228–229
Gifts
  on cultural basis, 72–73
  definition, 71
  extravagant, 72, 73
  holiday, 71–72
  motives, 72
  reasons for offering, 71–72
  seasonal Japanese, 72–73
  strategies for rejecting, 75
  thumb rules, 74
Global health care
  ethical dilemmas in, 94
  global burden of disease, 92
  harm from inexperienced trainees, 93
  informed consent, 93–94
  insufficient communication, 93
  principle of non-maleficence, 92–93
  technical and cognitive capabilities, 94
Good clinical practice (GCP) guidelines, 195

H
Hair growth, unwanted, 14, 16
Health care insurance, 163
The Health Insurance Portability and Accountability Act (HIPAA), 47
Help-seeking advertisement, 14
Hemangioma, infantile, 25, 28
Hospital consultations
  billing, 52
  disciplinary action or civil liability, 53
  hospital privileges, 53
  in-patient consultations, 53–54
  physician inconvenience, 52
  primary care physician, 51, 53

I
Impaired behavior
  aging, 103–104
  alcohol abuse, 101–102
  assessing physician, 100
Impaired behavior (cont.)
  disruptive behavior, 98, 103–104
  intervention, 99–100
  recovery contracts, 100–101
  substance use and mental illness, 99
Infantile hemangioma, 25, 28
Informal mentoring, 109–110
Informed consent
  epidermolysis bullosa, ethical practices, 211
  in pediatrics, 26
  in teledermatology, 47–48
Informed permission, 26
Innovative dermatology ventures (IDV), 177
Innovative therapy
  Belmont report, 237
  for cellulite, 238, 239
  clinical practice, 237
  clinical research, 237
  considerations, 238–239
  definition, 239
  investigational drugs, 238
  for Merkel cell carcinoma, 239–240
  rationale, 238
International Committee of Medical Journal Editors (ICMJE), 227
International Conference on Harmonisation (ICH), 194
International Ethical Guidelines for Biomedical Research
  Involving Human Subjects, 194
Internet, 79, 81, 82
Investigational new drug (IND), epidermolysis bullosa, 206
Isotretinoin and iPLEDGE, 20
  birth malformations, 20
  confidentiality, 21
  essential components of, 20, 21
  ethical concern, 20–21
  in minor, 22–23
  for nodulocystic acne, 20
  reproductive autonomy, 20
  right of conscience, 22
  Roche Pregnancy Prevention Program, 20
  for scarring nodular acne, chronic, 19
  youth risk behavior surveillance system, 21

J
Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 103
Journal of American Academy of Dermatology (JAAD), 229
Journal of Cutting-Edge Dermatology Research, 215–216
Journal of Investigative Dermatology (JID), 229

L
Lamellar ichthyosis (LI), TGM1 gene mutation, 197
Lentigo maligna, botulinum toxin injection, 134

M
Managed care organizations
  elliptical excision, 165
  gatekeeper system, 163–165
  health care insurance, 163
  nodular basal cell carcinoma, 164
  patient autonomy, primacy, 165
  patient-centered ethics, 166
  resource duties, 166
  telangiectasia, 163–164
  ulcerated lesion excision, 164
Mannose-binding lectin (MBL) gene, 199
Marketing, physician
  consumer advertisement, 147, 149
  cosmetic procedures, 147, 149–150
  deceptive advertising, 149
  ethical advertising and economic self-interest, 148
  merits and demerits, 148
  patient autonomy vs. paternalism, 149–150
  television advertisement, 147–149
  unsubstantiated advertising, 148–149
Mature minor, 27
Medical decision-making, 12
Medical education and communications companies
  (MECCs), 228
Medical fees, ethical and professional issues
  discounting, 155
  economic hardship, 155
  group practice, 153
  healthcare insurance, 154–155
  healthcare quality, 155
  health care system, cost control, 155
  history, 154
  insurance plan, 153
  patient ability, 154
  perversive/reverse sliding scale, 155
  public calling, 154
  sliding scale, 154, 155
  specialist visits, copayment for, 153
  threshold system, 155
  voluntary honoraria, 154
Medical spas, 158
Melanoma, malignant, 5, 9, 11–12
Mentoring. See Mentor-mentee relationship
Mentor-mentee relationship
  concept of, 109
  cultivation, 110
  good mentor qualities, 111
  informal mentoring, 109–110
  termination, 110–111
Merkel cell carcinoma, 33, 35–36, 239–240
Minors
  contraception for, 21
  isotretinoin on, 21
  privacy and confidentiality, 27–28
  rights of, 27
Moral, 52

N
National hiring standards, 11
National Resident Matching Program (NRMP), 114
Neurofibromatosis type 1, genetic testing, 198, 202
Nevus, dermal, 9, 11
Nevus, congenital facial, pediatric decision-making in, 26, 28–30
NF-1 neurofibromatosis, 4, 7
Nuremburg code, 194
Nurse practitioners (NP). See Physician extenders
Office dispensing and product pricing
benefits, 137, 138
dermatology, 137–138
economic value to customer, 140
opponents, 138
pharmaceutical supply chain, 139–140
practice’s profitability, 137
pricing methods, 137
primary considerations, 139
proponents, 138
purchasing cost, 140
reference value calculation, 140
supply chain, 140
transaction relationships, players, 141
Oral isotretinoin, for acne, 125
Parasitosis, delusions of, 34–35
Peutz Jeghers syndrome (PJS)
assent, 200–201
diagnostic testing, 201
novel treatments, 200
predictive testing, 200
pre-symptomatic testing, 200
pre-test counseling, 201
STK11 gene mutation, 197
symptoms, 199
Pharmaceutical supply chain, 139–140
Physician advertising. See Marketing, physician
Physician conscience, 85–86, 88
Physician extenders
economic factors, 57
guidelines, 56
real time on-site supervision, 57
residency-equivalent training, 57
survey, 56
TIME bill, 58
training, 56
Physician–patient dyad, 62
Physician–patient relationship
boundaries, 62
charitable donation, 64–65
fiduciary relationship, 64
post-consultation lingering, 63
slippery slope, 63
Physicians Health Programs (PHPs), 100
Plaque psoriasis, 9–11
Pod lab, 182
Post-publication criticism, 223
Post-publication review, 222
Prejudiced patients, 87
Prenatal testing, 199
Product claim advertisement, 14
Product pricing. See Office dispensing and product pricing
Professional boundaries, 62
Professional ethics, 52
Professionalism, 77, 80, 98–99
Professional issues. See Medical fees, ethical
and professional issues
Psoriasis
medication, 13, 15–16
plaque, 9–11
treatment
conflicts of interest, guidelines, 185, 188–189
effective therapy, 193–194
FDA-approved therapies, 194
Real time on-site supervision, 57
Recombinant DNA Advisory Committee (RAC), 206
Reminder advertisement, 14
Research Integrity Officer (RIO), 217
Residency interview
federal laws, 116
marital status, 115–116
national hiring standards, 115
National Resident Matching Program (NRMP), 114
risks and benefits of lying or being honest, 113–115
Residents, ethics education for
clinical teaching and medical ethics, 121
decision making, influences, 121
ethical obligation, 119, 122
ethical principles, 120–121
inexperience and knowledge gaps, 120
informed consent, 121
medicolegal consequences, 121
patient care, 119, 122
patient refusal, 119, 122
Residents, ethics education for (cont.)
  patients consent, 121–122
  personal identity, 120
  physician’s role, 119–120
  repair risks, 119, 122
Reviewer anonymity, 223
Roche Pregnancy Prevention Program, 20
Royal College of Physicians and Surgeons of Canada (RCPSC), 85

S
Salami-slicing, 234
Scientific publishing, 215, 216
Self-plagiarism
  copyright infringement, 234–235
  duplicate publication, 233–234
  elimination of, 236
  salami-slicing, 234
  solutions, 235–236
  text recycling, 235
Single-blind peer review, 222, 224
Skincare products
  anti-aging, 143
  application, 143–144
  cosmeceutical, 143
  developing and marketing, 144
  efficacy and ethical perils, 145
  ethical red flags, 144
  honest and scientific approach, 145
  patients, physicians and society, 144
Sliding scale fees, 154
Social media
  Facebook
    friending, 77, 78
    HIPAA violation, 79
    page and profile, 78
    patient-physician relationship, 78–79
    protected health information, 79
    student counsels, 81
    tagging photos on, 78, 82
    unprofessional online content, 80–81
    untagging photos, 78
  Web 2.0 application, 77
manager, 77
Social media manager, 77
Society of Dermatology Physician Assistants (SDPA), 56
Stark law, 181
Store-and-forward telemedicine, 46
Sulfonamide experiments, 193
Sunburn, 1, 6
Synchronous telemedicine, 45

T
T-cell lymphoma, cutaneous, conflicts of interest, 185, 189
Teaching, for clinical ethics
  health care cost, 126–127
  indigent patients care, 126
  insurer’s regulations, 126
  isotretinoin, 125, 127
Teledermatology
  confidentiality, 48
  definition, 46
  ethical issues, 46–48
  Health Insurance Portability and Accountability Act, 47
  informal, 46–47
  informed consent, 47–48
  medical information storage, 47
  protected health information, 47
  telemedicine types, 45–46
Telemedicine, 45–46
Termination, mentor-mentee relationship, 110–111
Text recycling, 235
Therapeutic privilege
  American Medical Association on, 34
  concept, 33
  consequentialist arguments, 34
  delusions of parasitosis, 34–35
  deontological arguments, 33–34
  insect infestation, 33
  Merkel cell carcinoma, 33, 35–36
TIME bill, 58
Trust, 84
Tuskegee syphilis study, 193
Twitter, 78

U
Ulcerated lesion excision, managed care, 164
Unprofessional online content, 80–81
Unreasonable demands for care, 9–10
Unsolicited medical opinion
  benefits and risks of, 5
  bystander phenomenon, 5
  conditions for offering, 7
  legal issues, 6
  malignant melanoma, 1, 6
  moral obligation, 5
  mutilating lesion, 4, 6–7
  NF-1 neurofibromatosis, 4, 7
  sunburn, 1, 6

W
Web 2.0 application, 77

Y
Youth risk behavior surveillance system, 21